Effects of nitric oxide donor antioxidants containing the phenol vitamin E substructure and a furoxan moiety on ischemia/reperfusion injury

Arzneimittel-Forschung/Drug Research

Volumn 59, Issue 3, 2009, Pages 111-116

  Di Stilo, Antonella ^a,b   Chegaev, Konstantin ^a   Lazzarato, Loretta ^a   Fruttero, Roberta ^a   Gasco, Alberto ^a   Rastaldo, Raffaella ^a   Cappello, Sandra ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Dipartimento di Scienza e Tecnologia del Farmaco   (Italy)

Author keywords

Antioxidants; Furoxans; Ischemia reperfusion; Multitarget drugs; Myocardial protection; Nitric oxide donors

Indexed keywords

ALPHA TOCOPHEROL DERIVATIVE; ANTIOXIDANT; NITRIC OXIDE DONOR;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; ISOLATED HEART; MALE; NONHUMAN; RAT; REPERFUSION INJURY; VASODILATATION;

EID: 66149162797     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296372     Document Type: Article

References (22)

1. Ambrosio G, Zweier JL, Duilio C, Kuppusamy P, Santoro G, Elia PP, et al. Evidence that mitochondrial respiration is a source of potentially toxic oxygen free radicals in intact rabbit hearts subjected to ischemia and reflow. J Biol Chem. 1993;268:18532-18541 (Pubitemid 23273786)
2. Chen Q, Vazquez EJ, Moghaddas S, Hoppel CL, Lesnefsky EJ. Production of reactive oxygen species by mitochondria. J Biol Chem. 2003;278:36027-36031
3. Becker LB. New concepts in reactive oxygen species and cardiovascular reperfusion physiology. Cardiovasc Res. 2004;61:461-470 (Pubitemid 38210152)
4. Margaill I, Plotkine M, Lerouet D. Antioxidant strategies in the treatment of stroke. Free Radical Biol Med. 2005;39:429-443 (Pubitemid 41021642)
5. Ebeerhardt K. Reactive oxygen metabolites: chemistry and medical consequence. Boca Raton: CRC Press; 2001.
6. Marczin N, El-Habashi N, Hoare GS, Bundy RE, Yacoub M. Antioxidants in myocardial ischemia-reperfusion injury: therapeutic potential and basic mechanisms. Arch Biochem Biophys. 2003;420:222-236 (Pubitemid 37491106)
7. Kutala VK, Khan M, Mandal R, Potaraju V, Colantuono G, Kumbala D, et al. Prevention of postischemic myocardial reperfusioin injury by the combined treatment of NCX-4016 and tempol. Cardiovasc Pharmacol. 2006;48:79-87. (Pubitemid 44562946)
8. Hamilton KL. Antioxidants and cardioprotection. Med Sci Sport Exer. 2007;39:1544-1553 and references therein.
9. Lefer AM, Hayward R. The role of nitric oxide in ischemia-reperfusion. In: Loscalzo J, Vita JA, eds. Nitric oxide and the cardiovascular system. Totowa: Humana Press; 2000. p. 357-380.
10. Schulz R, Kelm M, Heusch G. Nitric oxide in myocardial ischemia/reperfusion injury. Cardiovasc Res. 2004;61:402-413 (Pubitemid 38210147)
11. Iwase H, Robin E, Guzy RD, Mungai PT, Vanden Hoek TL, Chandel NS, et al. Nitric oxide during ischemia attenuates oxidant stress and cell death during ischemia and reperfusion in cardiomyocytes. Free Radical Biol Med. 2007;43:590-599 (Pubitemid 47058236)
12. Willmot M, Gray L, Gibson C, Murphy S, Bath PMW. A systematic review of nitric oxide donors and L-arginine in experimental stroke; effects on infarct size and cerebral blood flow. Nitric Oxide Biol Ch. 2005;12:141-149 (Pubitemid 40432134)
13. Das S, Falchi M, Bertelli A, Maulik N, Das DK. Attenuation of ischemia/reperfusion injury in rats by the anti-inflammatory action of resveratrol. Arzneimittelforschung. 2006;56:700-706
14. Boschi D, Tron GC, Lazzarato L, Chegaev K, Cena C, Di Stilo A, et al. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. J Med Chem. 2006;49:2886-2897 (Pubitemid 43749155)
15. Chegaev K, Lazzarato L, Rolando, B, Marini E, Tosco P, Cena C, et al. NO-donor melatonin derivatives: synthesis and in vitro pharmacological characterisation. J Pineal Res. 2007;42:371-385 (Pubitemid 46581662)
16. Cena C, Chegaev K, Balbo S, Lazzarato L, Rolando B, Giorgis M, et al. Novel antioxidant agents deriving from molecular combination of vitamin C and NO-donor moieties. Bioorg Med Chem. 2008;16:5199-5206
17. Bohn H, Brendel J, Martorana PA, Schönafinger K. Cardiovascular actions of the furoxan CAS1609, a novel nitric oxide donor. Br J Pharmacol. 1995;114:1605-1612
18. Mastrocola R, Aragno M, Betetto S, Brignardello E, Catalano MG, Danni O, et al. Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci. 2003;73:289-299 (Pubitemid 36579171)
19. Penna C, Alloatti G, Cappello S, Gattullo D, Berta G, Mognetti, B, et al. Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation. Am J Physiol Heart Circ Physiol. 2005;288:H2512-20. (Pubitemid 40604141)
20. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradykinin β2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling. Cardiovasc Res. 2007;75:168-177 (Pubitemid 46881061)
21. Feelisch M, Shönafinger K, Noack E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem Pharmacol. 1992;44:1149-1157
22. Razavi HM, Hamilton JA, Feng Q. Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and hearth failure. Pharmacol Ther. 2005;106:147-162 (Pubitemid 40613056)